ATOPIC DERMATITIS

This early-stage study is testing a new injectable medication called BxC-I17e for people with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and well-tolerated when given as single or multiple shots under the skin. Researchers will al…

This study aims to understand how well the medication dupilumab controls eczema (atopic dermatitis) and improves quality of life over two years in real-world settings. It will follow 900 patients in Germany, aged 6 and older, who are already starting this treatment. Researchers w…

This study is testing whether a new injectable drug called TRIV-509 can help control moderate to severe eczema (atopic dermatitis) in adults. About 90 participants will receive either the drug or a placebo injection for 16 weeks, then switch to the other treatment. The main goal …

This study is testing whether switching to a different medication helps adults with moderate-to-severe eczema who didn't get enough relief from their current dupilumab treatment. About 200 participants will try either upadacitinib pills or continue with dupilumab injections to se…

This study is testing whether a spray containing a harmless skin bacteria (Roseomonas mucosa) mixed with ground cardamom seeds can help control eczema symptoms. 120 participants aged 2 and older with eczema will spray the solution on their skin 2-3 times a week for 14 weeks, then…

This study follows patients with moderate-to-severe atopic dermatitis (eczema) who participated in earlier trials of afimkibart. It aims to understand the long-term safety and effectiveness of continued treatment. The study will track side effects and measure improvements in skin…

This study is testing whether a new oral medication called soquelitinib can safely reduce the rash and itch of moderate to severe eczema (atopic dermatitis). About 200 adults will take either the real pill or a placebo (a dummy pill with no medicine) daily for 12 weeks. Doctors w…

This study is testing which of two existing drugs works better to control moderate to severe eczema in children aged 2 to under 12. About 675 children worldwide will take either a daily pill (upadacitinib) or receive injections every few weeks (dupilumab) for up to three years. T…

This study is testing an investigational drug called galvokimig for adults with moderate-to-severe atopic dermatitis (eczema). Researchers will compare different doses of the drug against a placebo to see which works best at reducing skin inflammation and itching. The trial will …

This study is testing an investigational medication called GIA632 for adults with moderate to severe atopic dermatitis (eczema). Researchers will compare GIA632 against a placebo to see if it helps clear skin and is safe. The main goal is to see if participants' skin is clear or …

This study is testing a cream called ruxolitinib to see if it safely reduces the rash and severe itching of moderate eczema in children and teenagers aged 6 to 18. About 240 participants will use either the active cream or a placebo cream for 8 weeks to compare results. The main …

This study aims to see how safe and effective the daily pill abrocitinib is for treating moderate-to-severe eczema in real-world medical practice. It will follow about 180 adults with this chronic skin condition for two years while they take the medication. The goal is to underst…

This study is testing whether a new injectable drug called IBI3002 can safely reduce the itchy rash and inflammation of moderate-to-severe eczema (atopic dermatitis). About 120 adults with long-term eczema will receive injections of IBI3002, an approved drug (dupilumab), or a pla…

This study is testing whether a new drug called IMG-007 can help adults with moderate-to-severe eczema (atopic dermatitis) when standard topical treatments haven't worked well enough. 220 participants will receive either different doses of IMG-007 or a placebo for up to 52 weeks …

This study is testing whether children with well-controlled eczema can safely reduce the dose or completely stop their dupilumab injections. Researchers at Johns Hopkins will randomly assign 30 children, aged 1 to 17, to either continue their standard dose, take a lower dose, or …

This program provides eligible patients with access to the drug upadacitinib for conditions like Crohn's disease, ulcerative colitis, and atopic dermatitis before it is officially approved in their country. A doctor must determine if the potential benefits for an individual patie…

This study is testing a new laser device called PALLAS for treating skin conditions that often improve with UV light, including vitiligo, psoriasis, alopecia areata, and eczema. About 50 participants will receive targeted UVB laser treatments twice a week for up to three months. …

This is an early-stage study to check the safety and basic effects of a new drug called BBT001. It will first test single doses in healthy volunteers, then test repeated doses in adults with moderate to severe atopic dermatitis (eczema). The main goal is to see how well people to…

This study is testing a new oral medication, KT-621, for people with moderate to severe atopic dermatitis (eczema). For 16 weeks, some participants will receive the drug while others get a placebo, followed by a year where everyone can receive the active treatment. The main goals…

This study is testing whether adults with atopic eczema (atopic dermatitis) that is already well-controlled can safely take their dupilumab medication less often. Researchers will randomly assign 216 participants to receive their standard injection every 2 weeks, or to try extend…

This study is testing if a daily pill called Abrocitinib can help control eczema (atopic dermatitis) and patchy hair loss (alopecia areata) in people with Down Syndrome. It will enroll 56 participants aged 12 and older. The goal is to see if the treatment is safe and effective at…

This trial is testing whether an injectable drug called tralokinumab, when used with standard steroid creams, is safe and effective for controlling moderate-to-severe eczema in children and infants. It involves about 195 participants, from 6 months to under 12 years old, who have…

This study is testing a new drug called Afimkibart for people with moderate to severe eczema (atopic dermatitis). About 160 participants will receive either the drug or a placebo to see if it safely reduces skin inflammation and itching. The main goal is to see if the drug improv…

This study is testing whether following a healthy, balanced diet can help control eczema and related allergies. It will involve 110 adults in Singapore with mild-to-moderate eczema who will follow a specific meal plan for two months. Researchers will check if this diet improves s…

This study is testing if baricitinib, a drug used for other immune conditions, is safe for people with Job syndrome who also have lupus-like disease or a severe skin rash (atopic dermatitis). It will enroll about 20 participants aged 12 and older. The main goal is to check for si…

This study aims to see how well the approved drug nemolizumab works for people with moderate-to-severe eczema (atopic dermatitis) in real-world clinic settings. It will follow about 1000 adolescents and adults for up to a year, tracking their skin condition, itch, sleep, and pain…

This study is testing an investigational drug called IBI356 to see if it can reduce the rash and severe itching of moderate to severe atopic dermatitis (eczema). About 403 adult participants will be randomly assigned to receive either IBI356 or a placebo to compare effectiveness …

This is the first time a new drug called BGB-45035 is being tested in people. The main goal is to check if it is safe and how the body processes it. The study will first give the drug to healthy volunteers at different doses. Later, a small group of adults with itchy skin conditi…

This study is testing whether an oral medication called ICP-332 can effectively control moderate to severe atopic dermatitis (eczema) in adults. The trial will enroll 552 participants whose eczema hasn't responded well to standard topical treatments. Participants will receive eit…

This study is testing a cream called tapinarof to see if it is safe and effective for treating eczema in babies and toddlers aged 3 months to under 2 years. About 180 children will use the cream or a placebo for 8 weeks, followed by an open period where all can receive the active…

This small, early-stage study is testing if an oral medication called roflumilast can help control moderate-to-severe eczema (atopic dermatitis). For 12 weeks, 36 participants aged 12 and older will take the pill daily. Researchers will measure changes in skin rash, itch, and sle…

This study is testing whether a new oral drug called ZL-82 can help control moderate to severe atopic dermatitis (eczema) in adults. About 111 participants will take either ZL-82 or a placebo pill daily for 16 weeks to see if it reduces the severity of their skin rash and itching…

This study is testing how well the injectable medication lebrikizumab works for people with moderate eczema covering 10-25% of their body who experience severe daily itching. About 200 adults and teenagers will receive the medication for 6 months to see if it reduces their eczema…

This is the first time a new drug called PF-07832837 is being tested in people. The main goal is to see if it is safe and how the body handles it. The study will involve both healthy volunteers and people with moderate to severe atopic dermatitis (eczema) to check for side effect…

This two-year study aims to understand the long-term safety and effectiveness of an oral liquid medication called abrocitinib for children aged 2 and older with moderate-to-severe eczema (atopic dermatitis). It will enroll about 500 children globally, including some who have take…

This study is testing an investigational drug called FB825, given as five injections under the skin, to see if it can help control moderate-to-severe atopic dermatitis (eczema). It will involve about 90 adults whose eczema hasn't responded well to standard creams. The main goal i…

This study is testing two new injectable medicines (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) who haven't gotten enough relief from skin creams. Participants will receive either one of the study medicines or a placebo (inactive sho…

This study is observing how well the oral medication abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) in real-world clinics. It focuses on about 150 patients aged 12 and older who did not get enough relief or could not tolerate up to two previous bi…

This study aims to find out if an investigational drug called APG777 is safe and effective for long-term use in people with moderate-to-severe eczema (atopic dermatitis). It is open only to people who have already completed a previous study with APG777. The main goal is to monito…

This study is testing a new topical gel containing a specific strain of bacteria (Staphylococcus hominis A9) to see if it is safe and can help control eczema. It will enroll about 86 adults and adolescents with eczema who have a common 'bad' bacteria (Staphylococcus aureus) on th…

This study aims to understand how people in China actually use the eczema medication upadacitinib in everyday practice, outside of strict clinical trials. It will follow about 1000 adolescents and adults with moderate-to-severe eczema for approximately 12 months. Researchers will…

This study is testing several new medications for people with moderate to severe eczema (atopic dermatitis). Researchers will compare the experimental treatments against a placebo to see which works better at reducing skin inflammation and symptoms. The trial involves 224 partici…

This study is testing whether a new moisturizing cream called GX-03 can help control eczema symptoms better than a standard cream. About 100 adults with moderate to severe eczema will apply either GX-03 or a control cream twice daily for 8 weeks. Researchers will measure changes …

This is an early-stage study to check the safety of a new drug called BBT001 for people with moderate-to-severe eczema (atopic dermatitis). Researchers will give the drug to healthy volunteers and eczema patients in increasing doses to see how well it is tolerated and how it move…

This study is testing an investigational drug called ATI-045 to see if it can reduce the skin rash and severe itching of moderate-to-severe eczema (atopic dermatitis). About 96 adults who haven't gotten enough relief from standard creams will receive either the drug or a placebo …

This study is testing whether a moisturizer containing a probiotic called Lactobacillus reuteri can help improve eczema symptoms in children. Researchers will enroll 40 children aged 6 months to 12 years with moderate eczema. Participants will use the probiotic moisturizer for 8 …

This study is testing a new skin cream to see if it helps with dry, itchy skin conditions like eczema and psoriasis. Researchers will compare it to petroleum jelly, a common moisturizer, over 28 days. About 26 adults will apply the cream twice daily and have their skin checked we…

This study is checking if a medicine called dupilumab, already used for moderate-to-severe eczema, can also help improve anxiety and depression in people with this skin condition. It will observe about 184 patients from Gulf countries who are starting this treatment for 6 months.…

This study aims to understand if using ruxolitinib cream for eczema during pregnancy affects the baby's health. Researchers will compare pregnancy outcomes between women who used the cream and those who did not. The study is observational, meaning it tracks what happens naturally…

This study aims to better understand chronic hand eczema and atopic dermatitis by observing how the skin changes over time. Researchers will use non-invasive scans and collect skin samples from 270 participants, including people with these conditions and healthy volunteers. The g…

This study is creating a large international registry to track the long-term safety and real-world effectiveness of approved eczema medications in teenagers. It will follow about 1500 adolescents, aged 12-15, who have moderate to severe eczema and are starting a new treatment. Th…

This study aims to understand if and why the eczema medication dupilumab works differently in Caucasian, Asian, and African American patients. Researchers will enroll 30 adults with moderate-to-severe eczema to measure changes in their skin's immune response after starting the dr…

This study aims to find out how often adult atopic dermatitis (eczema) affects the eyelids, a common but poorly understood problem. Researchers will observe 550 adult patients in France to measure the frequency, describe the symptoms, and identify factors linked to eyelid involve…

This study aims to understand the community of microbes (like bacteria and fungi) that live on human skin and how they might contribute to eczema, also known as atopic dermatitis. Researchers are enrolling healthy volunteers and people with moderate to severe eczema, as well as p…

This study aims to understand the safety of a newer eczema cream (ruxolitinib) during pregnancy by comparing it to standard steroid creams. Researchers will analyze health insurance claims data from over 5,600 pregnant women in the US who have atopic dermatitis (eczema). The stud…

This study aims to learn how the body's immune system is connected to skin health and healing. Researchers will collect small skin samples and blood from adults with conditions like eczema, psoriasis, or immune deficiencies, as well as from healthy volunteers. The goal is to gath…

This is an observational study aiming to understand why food allergies develop and how they progress over time. Researchers will follow up to 1,800 participants, including people with food allergies, their relatives, and healthy volunteers, for many years. The study involves coll…

This study aims to understand why some people with eczema and related allergies like asthma and food allergies go into remission while others do not. Researchers will follow 1,000 participants, including healthy people, over time to collect health and lifestyle data. The goal is …

This study is testing whether a short, hands-on demonstration helps people with eczema use the right amount of prescription cream. Researchers will compare patients who get the special demo to those who receive standard written and verbal instructions. The goal is to see if bette…

This study aims to understand how doctors in France manage adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already receiving systemic (whole-body) medications. It will observe 600 patients in their regular care settings for one year, tracking whi…

This study is creating a registry to collect information from young people with eczema who are using or starting systemic (whole-body) treatments. The goal is to build a database that helps researchers understand which treatments work best, monitor safety, and quickly connect pat…

This early-stage study aims to understand how a new potential drug for atopic dermatitis (eczema), called CKD-706, behaves in the body compared to two versions of an existing drug, Dupixent. It involves 519 healthy adult volunteers who will receive a single dose. Researchers will…

This study aims to collect blood, urine, and skin samples from adults with specific skin conditions like cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The purpose is to build a collection of samples for researchers to study. By analyzing these samples, scientists hope …

This study aims to understand how eczema (atopic dermatitis) and food allergies might be connected biologically. Researchers will collect blood and skin samples from 200 people with different combinations of these conditions and healthy volunteers. The goal is to create a 'molecu…

This study is creating a large registry of patients with conditions like eczema, psoriasis, and alopecia areata to track how treatments work in real-world settings. Researchers will follow 15,000 adults and children over time to understand treatment safety, effectiveness, and how…

This study aims to understand how people with moderate-to-severe eczema (atopic dermatitis) respond to prescription treatments in everyday life, not in a controlled clinic. It will follow 1,000 patients aged 12 and older for five years across 10 countries, tracking which treatmen…

This study aims to understand if the eczema medication abrocitinib (CIBINQO) is safe for use during pregnancy. Researchers will follow 400 pregnant women with moderate-to-severe eczema—some taking the drug and some not—and track their babies' health through the first year of life…